FDA Approves Cosentyx for Polymyalgia Rheumatica
The approval adds a targeted option for adults with polymyalgia rheumatica who respond inadequately to corticosteroids, alongside a separate breast cancer approval.
Updated on Nov. 17, 2026 in Cancer

The U.S. Food and Drug Administration approved Novartis's Cosentyx 150 mg for adults with polymyalgia rheumatica who have an inadequate response to corticosteroids. The agency also approved Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer.
Why it matters
Cosentyx is the first and only anti-interleukin-17 biologic cleared for polymyalgia rheumatica, offering an alternative for patients who face long-term steroid risks such as osteoporosis, cardiovascular disease, and diabetes.
The Phase III evERA study reported a stratified hazard ratio of 0.38, equal to a 62% reduction in risk of progression or death for Wilserdly plus everolimus, with up to 40% of hormone receptor-positive metastatic breast cancer patients developing ESR1 mutations. The adjuvant use of Wilserdly is still under FDA review, and its outcome is not yet known.
The players
Novartis
Novartis is a Swiss multinational pharmaceutical company that develops and markets a wide range of prescription medicines, including the Cosentyx biologic.
Roche
Roche is a Swiss healthcare company and one of the world's largest pharmaceutical and diagnostics firms, known for its oncology portfolio.
U.S. Food and Drug Administration
The FDA is the U.S. federal agency responsible for approving drugs and biologics for safety and effectiveness before they reach the American market.
The details
Cosentyx is administered as a 150 mg dose for adult patients with polymyalgia rheumatica, and relapses strike up to 40% of patients within the first year. Wilserdly is an all-oral regimen combined with everolimus, and Roche's separate application for adjuvant use is based on the Phase III Lidera study and accepted under Priority Review.
Timeline
The FDA approvals were announced on November 15, 2026.
The PDUFA date for the Wilserdly adjuvant New Drug Application is November 30, 2026.
Roadmap
The Wilserdly adjuvant application, if approved, would be the first new adjuvant endocrine therapy in over 20 years and could establish a new standard of care for breast cancer. This places the Lidera trial results at the center of the next regulatory decision in endocrine-based breast cancer treatment.
Adults with polymyalgia rheumatica who cannot control symptoms with steroids may now have a targeted biologic option that avoids prolonged steroid exposure. Women with ESR1-mutated advanced breast cancer may gain a new all-oral combination treatment option once it reaches their clinic.
The takeaway
Patients with polymyalgia rheumatica who struggle with steroid dependence now have an additional targeted treatment to discuss with their physicians. Anyone with a breast cancer diagnosis should ask their care team whether ESR1 mutation testing is appropriate for their treatment planning.
What happens next
The FDA will review Roche's adjuvant Wilserdly application under a PDUFA date of November 30, 2026.
Further reading
Explore more on Cancer coverage and treatment developments.






